Actions of levodopa and dopamine in the central nervous system.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001665:Binding Sites; D001921:Brain / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects*; D002746:Chlorpromazine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000494:pharmacology* / Q000627:therapeutic use; D004298:Dopamine / Q000494:pharmacology* / Q000502:physiology; D000882:Haplorhini; D006834:Hydrazines / Q000494:pharmacology; D008781:Methyltyrosines / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000502:physiology*; D010300:Parkinson Disease / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D011950:Receptors, Cholinergic; D017981:Receptors, Neurotransmitter; D012110:Reserpine / Q000494:pharmacology; D013378:Substantia Nigra; D013569:Synapses; D009435:Synaptic Transmission
D006834:Hydrazines; D008781:Methyltyrosines; D018377:Neurotransmitter Agents; D011950:Receptors, Cholinergic; D017981:Receptors, Neurotransmitter; D004295:Dihydroxyphenylalanine; D012110:Reserpine; D001058:Apomorphine; D002746:Chlorpromazine; D004298:Dopamine